Tuberculosis remains a leading cause of death among women of childbearing age (20-59 years), killing 480 000 women in 2014 [1] . Estimates suggest that at least 216 500 pregnant women had tuberculosis disease in 2011 [2] . In sub-Saharan Africa, women of childbearing age have disproportionately high rates of human immunodeficiency virus (HIV) infection and, consequently, tuberculosis disease. The World Health Organization (WHO) estimates a 10-fold higher prevalence of tuberculosis disease among HIV-infected versus HIV-uninfected pregnant women in sub-Saharan Africa [1] , and in high-burden settings tuberculosis remains a leading cause of maternal death in HIVinfected women. However, identifying tuberculosis in pregnant women is challenging owing to altered symptoms and the low sensitivity of the WHO-recommended screening tool [3] [4] [5] .
Maternal tuberculosis disease has serious health consequences for both mothers and infants, particularly in the setting of HIV coinfection, with higher maternal and neonatal mortality rates and high proportions of prematurity and low birth weight (LBW) [6] [7] [8] [9] [10] [11] [12] [13] [14] . The combined effect of HIV and tuberculosis disease on obstetric and infant outcomes has not been reported in populations with high coverage of combined antiretroviral therapy (ART). We conducted a prospective cohort study to better describe the impact of tuberculosis disease among HIV-infected mothers on obstetric, neonatal, maternal, and infant outcomes in a population with access to ART. unconfirmed sputum smear and culture result) pulmonary and/or extrapulmonary tuberculosis disease were enrolled as case patients from 10 prenatal clinics associated with Chris Hani Baragwanath Academic Hospital. For each enrolled case patient, 2 HIV-infected pregnant women without tuberculosis were enrolled as controls, matched by age (±5 years), gestational age (±2 weeks), date of first prenatal visit (±8 weeks), and planned delivery clinic. All women were evaluated for tuberculosis at enrollment with the WHO symptom screen and 1 sputum mycobacterial culture (BACTEC MGIT 960 System). Any participant evaluated as a control who had a positive sputum culture for Mycobacterium tuberculosis at baseline was enrolled as a case patient, and 2 additional controls were recruited.
This study was noninterventional; all women and children received care in public-sector clinics in Soweto, according to South African ART and tuberculosis guidelines. Any discovered health problems were actively referred for appropriate evaluation and treatment.
Prevention and Treatment Guidelines for HIV and Tuberculosis
From 2011 through March 2013, the South African prevention of mother-to-child transmission of HIV guideline recommended WHO option A: efavirenz (EFV)-based ART when the CD4 cell count is ≤350/µL and zidovudine monotherapy, with single-dose nevirapine (NVP) at the initiation of labor, intrapartum zidovudine, and 1 postpartum dose of tenofovir (TDF) and emtricitabine (FTC) when the CD4 cell count is >350/ µL [15, 16] . Infants received NVP at birth and then daily for 6 weeks, if the mother had received ART, or for the duration of breastfeeding, if the mother had not received ART. In March 2013 after 173 women (74%) had been recruited, South Africa revised its guidelines for prevention of mother-to-child transmission, recommending option B with TDF, lamivudine or FTC, plus EFV either as prophylaxis for the duration of pregnancy and breastfeeding or lifelong ART for those with CD4 cell counts <350/µL or a stage 3 or 4 illness. All infants received NVP for 6 weeks. In 2010, South Africa moved from exclusive formula to exclusive breastfeeding as the primary recommendation for HIV-exposed infants. Commercial formula remained available and free of charge to this population for 6 months [17, 18] . Mixed feeding was defined as concurrent intake of both breast milk and any other liquid in the first 6 months.
Tuberculosis screening consisted of the WHO symptom screen and a sputum acid-fast bacterial smear for diagnosis. Treatment for drug-susceptible pulmonary tuberculosis consisted of 2 months of daily rifampicin, isoniazid, pyrazinamide, and ethambutol followed by 4 months of daily rifampicin and isoniazid, with standard weight-based dosing. Isoniazid preventive therapy was recommended but was not routinely provided to this population during the study period. Tuberculosis-exposed infants received either 3 months of isoniazid and rifampin or 6 months of isoniazid monotherapy as prophylaxis [19, 20] .
Data Collection
All women were followed up for obstetric, HIV, and tuberculosis outcomes. Infants were followed up for birth, HIV, tuberculosis, and clinical outcomes. Mothers were assessed during the second and third trimesters and mother-infant pairs at 1 week, 6 weeks, 6 months, and 12 months after delivery. Maternal and infant outcomes were confirmed from maternity, tuberculosis, and hospital records, and the infant's road to health card. Gestational age was determined by the date of the last menstrual period. At each scheduled postpartum visit, anthropometric measures, a feeding assessment, tuberculosis and opportunistic infection screening, and a review of hospitalizations were performed for each mother-infant pair. In additional, maternal HIV RNA measurement (COBAS AmpliPrep/COBAS TaqMan HIV-1 Test), maternal CD4 cell count (dual-platform technology), and infant qualitative HIV DNA polymerase chain reaction analysis was performed at each postpartum visit. When HIV positive, the infant returned for CD4 cell count and quantitative HIV RNA measurement. Laboratory testing was performed by Clinical Laboratory Services, an accredited commercial laboratory.
Infants with suspected tuberculosis were assessed by a pediatrician and underwent tuberculin skin testing, chest radiography, and gastric aspirate for acid-fast bacterial smear, mycobacterial culture, and/or Gene Xpert in the public sector. Congenital tuberculosis was defined according to the criteria described by Cantwell et al [21] . Infant tuberculosis was classified as confirmed, probable, or possible tuberculosis based on standard criteria [22] . The study was approved by institutional review boards of Johns Hopkins Medicine and the University of Witwatersrand.
Statistical Analysis
Data were analyzed using SAS statistical software (version 9.3) [23] . To compare outcomes in HIV-infected pregnant women with or without tuberculosis and their infants, we used Pearson χ 2 or
Fisher exact tests for categorical variables and Student t or MannWhitney U tests for continuous variables. Primary outcomes of maternal death and mother-to-child transmission of HIV were not common enough to allow for multivariate analysis as planned. The prespecified maternal complication composite outcome includes pregnancy-induced hypertension, antepartum hemorrhage, prolonged rupture of membranes, unplanned cesarean, puerperal sepsis, maternal death, spontaneous abortion (fetal death at <28 weeks), stillbirth (fetal death at ≥28 weeks), prematurity (delivery at <37 weeks), LBW (<2.5 kg), small size for gestational age (<10th percentile), perinatal death, and fetal abnormalities. The prespecified infant complication composite outcome includes perinatal or neonatal death, neonatal sepsis (<90 days), tuberculosis within the first 6 months of life, infant hospitalization, and infant death.
RESULTS
A total of 80 HIV-infected pregnant women with tuberculosis disease (case patients) and 155 matched HIV-infected pregnant women without tuberculosis (controls) were enrolled. Delivery outcomes were not available for 7 women owing to withdrawal of consent (n = 3), loss to follow-up (n = 1), or relocation (n =3) ( Figure 1 ). Here we present the maternal outcomes in 77 case patients and 151 controls who were followed up through delivery. Of the 74 and 150 live births among maternal case patients and controls, 8 infants (3.6%) were not followed up after delivery owing to death (n = 3), withdrawal of consent (n = 1), loss to follow-up (n = 3), or relocation (n = 1). Thirty infants did not complete a year of follow-up owing to death (n = 3), withdrawal of consent (n = 1), loss to follow-up (n = 5), relocation (n = 14), or other reasons (n = 8). Losses were similar among the 2 groups with completion of follow-up in 82% and 83% of infants born to maternal case patients and controls (P = .97).
Maternal Characteristics at Enrollment
Case patients and controls had similar characteristics at enrollment, with a median maternal age of 29 years (interquartile range [IQR], 26-31 years), a median gestation of 30 weeks (26-34 weeks), and similar parity and racial, socioeconomic, and educational backgrounds (Table 1) . Similar proportions of maternal case patients (68.8%) and controls (63.2%) were receiving ART at enrollment (P = .30), although case patients had a lower median CD4 cell count (242/µL; IQR, 137-379/µL) than controls (369/µL; 263-476/µL; P < .001) and a smaller proportion of case patients were virally suppressed (30.8%) compared with controls (47.7%; P < .001). At delivery, a larger proportion of case patients (87.0%) than controls (72.1%) had started ART (P = .01). Anemia was more common among case patients (27.5%) than among controls (11.0%; P = .001).
Among the 162 women evaluated for the control group, 7 (4%) had sputum cultures in which M. tuberculosis grew, of whom 1 was sputum smear positive (scanty); the median time to liquid culture positivity was 17 days (range, 10-31 days). Their enrollment category was modified from control to case patients. None of these women reported symptoms of tuberculosis, and all denied prior episodes of tuberculosis.
Among maternal case patients, 73 (91.3%) had pulmonary tuberculosis, of which 36 cases (59.3%) were confirmed, 14 (19.2%) were probable, and 23 (31.5%) were possible tuberculosis. One case patient had disseminated tuberculosis, 3 had pleural tuberculosis, 2 had tuberculous lymphadenitis, 1 had pericardial tuberculosis, and 1 had combined pulmonary and abdominal tuberculosis ( Table 1) . There were no cases of multidrug-resistant tuberculosis, and 92.3% of tuberculosis cases were treated with rifampin, isoniazid, pyrazinamide, and ethambutol. The majority of women had tuberculosis diagnosed during pregnancy (Table 1) and nearly all started tuberculosis therapy during pregnancy, except 3 (3.8%) in whom tubercolosis was diagnosed by our study during enrollment.
Maternal Outcomes
Preeclampsia was 8-fold more common among case patients than among controls (5.2% vs 0.7%; P = .03; Table 2 ). Pregnancyrelated conditions, including pregnancy-induced hypertension, antepartum and postpartum hemorrhage, and prolonged rupture of membranes, did not differ significantly between case patients and controls. Modes of delivery including unplanned (14.9% and 18.1%, respectively) cesarean section and forceps-assisted delivery (1.3% and 0%, respectively; P = .42) did not differ significantly between case patients and controls.
During follow-up, a higher proportion of case patients than controls were hospitalized before (25.0% vs 11.0%; P = .005), during (8.8% vs 1.3%; P < .005), or after delivery (12.5% vs 1.9%; P < .001; Table 2 ). Only 8.1% of hospitalizations in maternal case patients were due to tuberculosis. During the 1-year follow-up, 3 case patients (3.9%) had relapsed tuberculosis, 1 with multidrug-resistant tuberculosis.
Maternal mortality rates were low, with 1 death in each group, resulting in maternal mortality ratios of 1351 and 667 per 100 000 live births among case patients and controls, respectively (P = .63). One case patient and 1 control died during the first year of follow-up, resulting in late maternal mortality rates of 2.8 and 1.5 deaths per 100 person-years among case patients and controls, respectively (P = .28).
Neonatal Outcomes
The median birth weight was significantly lower among infants born to case patients (2950 g; IQR, 2550-3270 g) than to controls (3060 g; 2750-3330 g; P = .04); indeed, infants born to case patients (20.8%) were twice as likely to have LBW (<2500 g) than those born to controls (10.7%; P = .04). The proportion of infants who were small for gestational age was nearly 50% greater among case patients (31.4%) than among controls (21.9%), though this difference was not statistically significant (P = .14). There were no differences in birth outcomes including live births, stillbirths, and spontaneous abortion among case patients (96.1%, 1.3%, and 2.7%, respectively) and controls (98.7%, 1.3%, and 0%; P = .29; Table 2 ). Rates of preterm (32 to <37 weeks; 17.6% and 15.3%, respectively) and very preterm (28 to <32 weeks; 2.7% and 1.3%; P = .69) births were similar among case patients and controls (Table 3) . No infants were born extremely premature (<28 weeks).
Neonates born to maternal case patients had higher rates of prolonged hospitalization at birth (51% vs 16%, respectively; P < .001) and more admissions to the neonatal intensive care unit (9.5% vs 2.7%; P = .03). There were no differences in neonatal mortality rate, neonatal sepsis, or congenital infection (P > .6; Table 3 ).
Infant HIV Transmission
NVP prophylaxis was initiated shortly after birth and continued for at least 6 weeks in 98% of case patients and 95% of controls (P = .20). Infant feeding was similar among the 2 groups, with two-thirds of infants formula fed (67% for case patients vs 61% for controls), one-third exclusively breast-fed (32% vs 36%), and a small proportion receiving mixed feedings (1% vs 3%; P = .66; Table 4 ).
The proportion of infants who acquired HIV infection was higher among infants born to case patients (4.1%) than to controls (1.3%), although this difference was not statistically significant (P = .20; Table 3 ). No HIV infections were diagnosed in the first week of life. Three were identified at 6 weeks, 2 with delayed maternal ART initiation and 1 with mixed feeding. The final 2 infections were identified among breast-fed infants at 6 months (Supplementary Table S1 ).
Infant Tuberculosis Transmission
Tuberculosis preventive therapy was initiated in 81% of infants born to case patients (Table 4) ; regimens included 3 months of isoniazid/rifampicin (80%) or 6 months of isoniazid (20%). Caregivers reported completion of therapy in 75% and 42% of those prescribed the 3-month and 6-month regimens, respectively (P = .03).
Nine infants (12%) were treated for tuberculosis disease in the first year of life, all born to maternal case patients (P < .001; Supplementary Table S2). One infant had tuberculosis meningitis, and 8 had pulmonary tuberculosis, of which 1 case was confirmed. No congenital tuberculosis was diagnosed. Preventive therapy was not completed in 1 patient and was stopped early in 2 others owing to a tuberculosis diagnosis. Only 3 infants had identified household contacts.
Infant Outcomes
The infant mortality ratio among maternal case patients was 10-fold that among controls (5 deaths and 68 deaths per 1000 births vs 1 death and 7 deaths per 1000 births, respectively; P < .001; Table 3 ). Two deaths were due to significant congenital anomalies, 1 was due to respiratory distress, and 3 were related to gastroenteritis with dehydration (Supplementary Table S3 ). 
DISCUSSION
This study of tuberculosis in HIV-infected pregnant women in the era of combination ART demonstrates 4 principal findings.
First, infants born to HIV-infected mothers with tuberculosis disease had increased rates of LBW, prolonged hospitalization at birth, and higher infant mortality rates. Second, infants born to maternal case patients had a higher risk of tuberculosis disease despite appropriate maternal tuberculosis therapy and Both groups were HIV infected; the control group did not have tuberculosis. Data represent no. (%) of neonates or infants unless otherwise specified. b Small size for gestational age was calculated using WHO-defined standards [25, 26] . Prolonged hospital stay at birth was defined by local standards, with an expectation that mother-infant pairs would be admitted for ≥2 days for vaginal delivery and ≥4 days for cesarean section [24, 25, 26] .
receipt of tuberculosis preventive therapy. Third, obstetric outcomes in coinfected women were poorer, with higher rates of maternal hospitalization and preeclampsia. Fourth, there was a trend toward higher rates of mother-to-child HIV transmission among infants born to HIV-infected mothers with tuberculosis disease, though this was not statistically significant. Infants born to mothers with tuberculosis disease had a 10-fold increased infant mortality risk. Although these deaths were largely attributable to gastroenteritis, the rates of formula feeding, a known risk factor for gastroenteritis in this setting [27] [28] [29] , were similar in both groups. Importantly, tuberculosis may have been a cause of their gastrointestinal symptoms.
Tuberculosis disease in pregnancy is known to cause increased perinatal death, preterm delivery, and LBW infants [8, 9] ; untreated HIV compounds these risks [7, 30] . Despite widely available ART, the risk of LBW and prolonged hospitalization at birth persisted with maternal tuberculosis disease. Specific ART regimens have also been associated with stillbirth, preterm delivery, and small size for gestational age [31, 32] , however these effects may be minimal, because as the majority of women in both groups were receiving TDF-FTC-EFV, the regimen least associated with these outcomes [31] . Combined maternal ART and tuberculosis therapy may partially reverse the risk associated with untreated maternal HIV infection and comorbid tuberculosis disease.
Mothers with comorbid tuberculosis disease had significantly higher rates of preeclampsia and hospitalization, with a trend toward more spontaneous abortions and stillbirths. Although HIV has not been associated with preeclampsia [33] , other infections have been, though the mechanism of this association remains unknown [34] .
Maternal death was fortunately rare among case patients and controls. By 2010, the South African maternal mortality ratio was already improving (430 per 100 000 live births), attributed to improved ART coverage [35] . Nationally, tuberculosis remains a leading cause of maternal death, but among the patients in our cohort with diagnosed and treated tuberculosis, death was not common.
Our cohort demonstrates a trend toward higher HIV transmission among infants born to case patients (4.1%) than among those born to controls, far lower than the 19% reported in the pre-ART era [30] . Gupta et al [36] demonstrated a 2.5-fold increase in HIV transmission among mothers with predominantly postpartum tuberculosis, but again <10% of mothers in that study were receiving ART. Our study took place mostly during South Africa's option A era, leading to an expected imbalance of maternal ART among case patients (WHO stage III illness) compared with controls. Despite the lower rates of ART initiation among controls, MTCT of HIV remained low (1.3%). Although the mechanism of perinatal HIV transmission among infants born to maternal tuberculosis case patients is unknown, these transmissions seem to be due to late treatment, nontreatment, or nonadherence, and not drug-drug interactions, including infant rifampin and NVP prophylaxis [37] .
Infants born to maternal case patients remained at high risk of tuberculosis disease throughout infancy, despite appropriate maternal therapy and reported completion of infant tuberculosis prophylaxis. Their higher risk of tuberculosis disease could be due to continued household transmission through undiagnosed household contacts, community exposure [38, 39] , or poor adherence to prescribed tuberculosis prophylaxis. Evidence suggests that HIV-exposed uninfected infants may be at higher risk of tuberculosis disease [40, 41] , but this risk was not demonstrated among the HIV-exposed uninfected controls.
Our data support the insufficient sensitivity of the WHO symptom screen for the detection of tuberculosis disease among HIV-infected pregnant women [3] [4] [5] . This continues to present a challenge in high-incidence, low-resource settings, which rely on symptomatic screening to identify women who require further investigation. Evaluating HIV-infected pregnant women in high-incidence settings with universal sputum testing may be necessary to screen for and identify tuberculosis disease. Tuberculosis preventive therapy during pregnancy may also play an important role in tuberculosis prevention in this high-risk group, although care would need to be taken to first rule out active disease. Because this study was conducted in Soweto, an urban setting with relatively good obstetric, medical, and pediatric health care, and during South African's implementation of option A, the generalizability of our results may be limited. Another important limitation of our cohort is that our recruited sample size had insufficient power to detect small differences between groups, for example, mother-to-child HIV transmission. Finally, our recruitment and follow-up procedures limited our ability to confirm all maternal and infant tuberculosis episodes before the initiation of antituberculous therapy, and we cannot link maternal and infant tuberculosis cases genetically.
Tuberculosis in HIV coinfected pregnant women remains a significant threat not only to their own health, but also to the health of their fetus and infant. Improving implementation of tuberculosis preventive therapy and early detection of tuberculosis disease among pregnant women is critical. Our data suggests that HIV-infected pregnant women with tuberculosis should have close medical attention during pregnancy and delivery, and their infants should be closely followed up for HIV transmission, tuberculosis and general well-being in addition to receiving tuberculosis preventive treatment.
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